BIOMARIN PHARMACEUTICAL INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.2B | $2.9B | $2.4B | $2.1B | $1.8B |
| Cost of revenue | $717.4M | $580.2M | $532.1M | $503.0M | $470.5M |
| Selling, general & administrative | $1.2B | $1.0B | $892.4M | $823.2M | $759.4M |
| Research and development | $921.9M | $747.2M | $746.8M | $649.6M | $628.8M |
| Operating income | $409.5M | $484.2M | $185.8M | $161.0M | -$82.3M |
| Interest expense | $10.9M | $12.7M | $17.3M | $16.0M | $15.3M |
| Pretax income | $482.5M | $541.8M | $188.6M | $149.6M | -$75.3M |
| Income tax expense | $133.6M | $114.9M | $20.9M | $8.0M | -$11.3M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | -$64.1M |
| Balance Sheet | |||||
| Cash and equivalents | $1.3B | $942.8M | $755.1M | $724.5M | $587.3M |
| Current assets | $4.0B | $3.2B | $3.0B | $2.8B | $2.3B |
| Total assets | $7.6B | $7.0B | $6.8B | $6.4B | $6.0B |
| Current liabilities | $759.0M | $607.0M | $1.2B | $588.9M | $546.5M |
| Total liabilities | $1.5B | $1.3B | $1.9B | $1.8B | $1.7B |
| Total debt | $600.0M | $600.0M | $1.1B | $1.1B | $1.1B |
| Stockholders' equity | $6.1B | $5.7B | $5.0B | $4.6B | $4.3B |
| Cash Flow Statement | |||||
| Cash from operations | $828.0M | $572.8M | $159.3M | $175.9M | $304.5M |
| Depreciation and amortization | $79.6M | $96.4M | $104.4M | $102.0M | $108.0M |
| Stock-based compensation | $181.4M | $201.6M | $207.1M | $196.3M | $197.3M |
| Capital expenditure | $103.0M | $85.4M | $96.7M | $121.0M | $95.6M |
| Free cash flow | $725.0M | $487.4M | $62.6M | $54.9M | $209.0M |
| Share repurchases | — | — | — | $0 | $0 |
| Impairments | $125.0M | $19.9M | $38.6M | $0 | $0 |
Shares outstanding 193.3M · Free float 80.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.